骨髄腫
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667.PMID: 31270103 ダラツムマブはCD38を標的としたヒトモノクローナル抗体であり、多発性骨髄腫(MM)患…
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.PMID: 31433920 背景核外搬出化合物の選択的阻害薬であるselinexorは、exportin 1 (XPO1)をブロックし…
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.Blood. 2019 Jun 20;133(25):2664-2668.PMID: 31010846 doi: 10.1182/blood.2019000671. 多発性骨髄腫(MM)の治療効果判定クライテリ…
Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. Bone Marrow Transplant. 2019 Feb 4 PMID: 30718802 D…
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 1;37(7):589-597 PMID: 30653422, DOI: 10.1200/JCO.18.00685 目的 メルファラン 200 mg/m2の投与と…
Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients doi: 10.1182/blood-2018-09-874396 第3相試験であるCLARION試験は,移植非適応の未治療多発性骨髄腫患者を対象とし,カルフィ…
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. PMID: 30237266, PMCID: PMC6355495, DOI: 10.3324/haematol.2018.200881…
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822 PMID: 30403938, doi: 10.1056/NEJMoa1805762. 背景 免疫賦活性モノクローナル抗体であるエロツズマブにレナリドミドとデキサメタゾンを…
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Blood. 2017 Aug 24;130(8):974-981. www.ncbi.nlm.nih.gov 2種類以上の前治療歴があり、直近の治療が効かなかった再発・難治性の多発性骨髄腫の患者を対…
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial J Clin Oncol 2018 www.ncbi.nlm.nih.gov 目的腎障害(renal impairment; RI)は再発・難治性骨髄腫(…
ダラツムマブdaratumumab(ダラザレックス®)は、日本では2017年9月に承認されたばかりの新薬で、今のところ再発・難治性の多発性骨髄腫に適応があります。 Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaN Engl J Med 2018;3…
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018, doi: 10.1200/JCO.2017.75.5207. 目的selinexorは画期的な新薬で、exportin 1 (XPO1)を選択的に阻害し、腫瘍蛋…
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.Blood. 2017 Dec 14;130(24):2610-2618. いくつかの細胞遺伝学的異常は骨髄腫の予後に悪影響を及ぼすことが知られている。第3相試験であるTO…
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. (Blood. 2017 Sep 7;130(10):1189-1197.) Programmed death 1 (PD-1)受容体とそのリガンド(PD-L1)は多発性骨髄腫(MM)における免疫からの回避を助長して…
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Br J Haematology 2017 PMID: 28169430, DOI: 10.1111/bjh.1453…
Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy Eur J Haematol. 2017;98:149-153. PMID: 27717026, DOI: 10.1111/ejh.12813 www.ncbi.nlm.nih.gov 目的 血流感染(BSI)は多発性骨髄腫(MM)治療における重篤…
Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis PMID: 28178364, DOI: 10.1111/ejh.12868 www.ncbi.nlm.nih.gov 目的 著者らは、新規に…
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101:1398-1406. www.ncbi.nlm.nih.gov 高齢の多発性骨髄腫に対する自家移植は議論の余地があ…
Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines. Blood. 2016, PMID 27729323 www.ncbi.nlm.nih.gov 軽鎖のみを発言している骨髄腫(light chain multiple myeloma; LCMM)のモニ…
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leuk Lymph…
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. (Lancet Haematol. 2016, PMID 277517…
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (N Engl J Med. 2016;375:1319-1331) www.ncbi.nlm.nih.gov 背景 daratumumabは、再発・難治骨髄腫患者を対象とした第1、2相試験において、単剤、またはレナリドミドとデキサメタゾンと…
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. www.ncbi.nlm.nih.gov 背景 骨髄腫細胞は一様にCD38を発現している。著者らはCD38を標的としたヒトIgG1κ型モノクローナル抗体であるdaratumumabについて、再発骨髄腫または再発後2種類以…
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. www.ncbi.nlm.nih.gov 背景 ダラツムマブはCD38を標的としたヒトIgGκ型モノクローナル抗体であり、直接的、間接的に抗骨髄腫活性を誘導し、濃…
Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma (Haematologica 2014;99:1846-1853) 多発性骨髄腫の経過において、初発時と異なるM蛋白のバンド:二次性のMGUS(monoclonal …
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study (Lancet Haematol 2015;2:e30-36…
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma (Br J Harmatol 2015;168:46-54) この単施設,オープンラベル第I/II相用量増量試験では,再発・難…
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (NEJM, DOI: 10.1056/NEJMoa1411321) 背景 レナリドミド+デキサメタゾンは骨髄腫再発時において基準となる治療である.プロテアソーム阻害薬であるcarfilzomibをレナリドミド…
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomis…
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. (Blood 2014;124:63-69) この多施設参加、オープンラベル第2相試験では、新たに診断された65歳以上または自家幹細胞…